Clinical Trials Directory

We are doing this study to compare the outcomes of 2 treatments for women with stress urinary incontinence (SUI): transurethral bulking agent (TBA) and single-incision sling (SIS). Both treatments are FDA-approved and can help improve SUI symptoms, but they have not been directly compared to each other to see which treatment is better for certain patients and under what circumstances. We hope this study can help women and their doctors find out which option is most likely to have the best results. Current evidence suggests that TBA and SIS are less effective than a traditional full-length mid-urethral sling procedure, but both options are less invasive and less likely to cause complications afterward.

We are doing this study to find out if an investigational drug called TP-3654 (the study drug) is a safe and effective treatment for myelofibrosis. The study drug will be tested at different doses to find out what effects, if any, it has on myelofibrosis.

We are doing this study to find the most effective, safe dose of an experimental drug called ficerafusp alfa (BCA101 - the study drug) when it is given in combination with pembrolizumab for people who have metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).

We are doing this study to find out if an experimental drug called brepocitinib (the study drug) is a safe and effective option for people with cutaneous sarcoidosis.

We are doing this study to find out if an experimental drug called BGB-43395 (the study drug) is a safe and effective option for people with for breast cancer and other advanced solid tumors. We want to know how the study drug works on its own and in combination with other cancer drugs.

We are doing this study to find the most safe and effective long-term dose of an experimental drug called zanubrutinib (the study drug) when it is given alone or in combination with other cancer drugs. We want to know how well this study drug works in people with B-cell cancers who are currently participating or previously participated in a BeiGene-sponsored study.

We are doing this study to monitor the health of the cornea in participants with neovascular age-related macular degeneration (nAMD), also know as wet AMD, who receive an eye implant that continuously delivers the drug ranibizumab into the back of the eye.

We are doing this study to see if the combination of an experimental drug called BGB-3245 (the study drug) and panitumumab is a safe and effective option for patients who have colorectal or pancreatic cancer with an RAS mutation.